Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06794840 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

JomCare Study - A Harm Reduction Study

Study acronym: JomCare
StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Apr 1, 2026 to Nov 1, 2026
    • Eligibility criteria expanded, about 8 words
    • Publications: details revised at 2 of 2 entries
  2. Start date: Oct 1, 2025 to Apr 1, 2026
    • Publications: details revised at 2 of 2 entries
    v4
  3. Start date: Jun 1, 2025 to Oct 1, 2025
    • Publications: details revised at 2 of 2 entries
    v3
  4. Primary endpoint revised
    • Study description expanded, about 3 words
    • Study title expanded, about 2 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Chemsex, the use of psychoactive drugs before or during sexual activity, is a growing public health concern associated with striking increases in HIV, particularly among men who have sex with men (MSM). This study proposes to optimize an app-based just-in-time adaptive intervention, called JomCare, which aims to reduce chemsex risk by delivering tailored support when a person is most likely to be vulnerable to chemsex risk behaviors and receptive to intervention, with the purpose of reducing risk and averting new HIV infections.
Trial Details
NCT Number NCT06794840
Lead Sponsor University of Connecticut
Collaborators: University of Malaya, Yale University, National Institute on Drug Abuse (NIDA), University of Michigan, University of Texas at Tyler, Ohio State University
Conditions
(from sponsor)		 HIV, Substance Abuse Disorder
Related terms Chemsex, Substance-Related Disorders
Enrollment 482 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov